MeiraGTx Holdings PLC (NASDAQ:MGTX) has earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a one year consensus target price of $40.00 for the company, according to Zacks. Zacks has also assigned MeiraGTx an industry rank of 84 out of 256 based on the ratings given to related companies.
A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of MeiraGTx from a “buy” rating to a “sell” rating in a research note on Wednesday, May 29th. Chardan Capital reiterated a “buy” rating on shares of MeiraGTx in a research note on Tuesday, May 14th. Barclays lifted their price target on shares of MeiraGTx from $20.00 to $30.00 and gave the stock a “positive” rating in a research note on Wednesday, May 15th. Finally, ValuEngine downgraded shares of MeiraGTx from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st.
Institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new stake in MeiraGTx in the 4th quarter valued at $1,928,000. BlackRock Inc. raised its position in MeiraGTx by 23.5% in the 4th quarter. BlackRock Inc. now owns 178,769 shares of the company’s stock valued at $1,723,000 after purchasing an additional 34,070 shares during the last quarter. JPMorgan Chase & Co. raised its position in MeiraGTx by 2,008.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 171,168 shares of the company’s stock valued at $4,338,000 after purchasing an additional 163,050 shares during the last quarter. Sawtooth Solutions LLC raised its position in MeiraGTx by 28.3% in the 1st quarter. Sawtooth Solutions LLC now owns 137,315 shares of the company’s stock valued at $2,366,000 after purchasing an additional 30,328 shares during the last quarter. Finally, EAM Global Investors LLC purchased a new stake in MeiraGTx in the 1st quarter valued at $979,000. Institutional investors own 35.36% of the company’s stock.
Shares of MGTX stock traded down $4.09 during trading on Thursday, reaching $21.49. The company’s stock had a trading volume of 33,516 shares, compared to its average volume of 122,980. MeiraGTx has a 1-year low of $8.16 and a 1-year high of $30.23. The company has a 50-day simple moving average of $26.68. The company has a quick ratio of 6.96, a current ratio of 6.96 and a debt-to-equity ratio of 0.02. The firm has a market cap of $828.68 million, a P/E ratio of -4.91 and a beta of 1.99.
MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.47). The company had revenue of $1.98 million for the quarter.
MeiraGTx Company Profile
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
See Also: Buy Rating
Get a free copy of the Zacks research report on MeiraGTx (MGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.